Region:Middle East
Author(s):Shubham
Product Code:KRAE0462
Pages:86
Published On:December 2025

By Type:The sustained release excipients market is segmented into various types, including natural polymers, synthetic polymers, lipid-based excipients, and others. Among these, synthetic polymers are currently dominating the market due to their versatility and ability to provide tailored release profiles for various drug formulations. The increasing demand for customized drug delivery systems is driving the growth of synthetic polymers, as they can be engineered to meet specific therapeutic needs.

By End-User:The market is also segmented by end-users, which include pharmaceutical companies, contract manufacturing organizations, research institutions, and others. Pharmaceutical companies are the leading end-users, driven by the increasing need for innovative drug formulations and the growing prevalence of chronic diseases. Their focus on developing advanced drug delivery systems is significantly contributing to the demand for sustained release excipients.

The Middle East Sustained Release Excipients Market is characterized by a dynamic mix of regional and international players. Leading participants such as BASF SE, Evonik Industries AG, Ashland Global Holdings Inc., Dow Chemical Company, Croda International Plc, FMC Corporation, Merck KGaA, JRS Pharma, Roquette Frères, Ingredion Incorporated, Colorcon, HPM Global, Lubrizol Corporation, Sensient Technologies Corporation, Sentrachem contribute to innovation, geographic expansion, and service delivery in this space.
The future of the sustained release excipients market in the Middle East appears promising, driven by ongoing advancements in drug formulation technologies and a growing emphasis on personalized medicine. As healthcare systems increasingly adopt innovative therapies, the demand for tailored drug delivery solutions is expected to rise. Additionally, collaborations between pharmaceutical companies and research institutions are likely to foster the development of novel excipients, enhancing the efficacy and safety of drug formulations in the region.
| Segment | Sub-Segments |
|---|---|
| By Type | Natural Polymers Synthetic Polymers Lipid-based Excipients Others |
| By End-User | Pharmaceutical Companies Contract Manufacturing Organizations Research Institutions Others |
| By Application | Oral Drug Delivery Injectable Drug Delivery Transdermal Drug Delivery Others |
| By Formulation Type | Tablets Capsules Suspensions Others |
| By Distribution Channel | Direct Sales Distributors Online Sales Others |
| By Geography | GCC Countries Levant Region North Africa Others |
| By Regulatory Compliance | FDA Approved Excipients EMA Approved Excipients Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Pharmaceutical Manufacturers | 150 | R&D Managers, Production Heads |
| Regulatory Bodies | 50 | Regulatory Affairs Officers, Compliance Managers |
| Raw Material Suppliers | 100 | Sales Managers, Product Development Specialists |
| Contract Research Organizations (CROs) | 80 | Project Managers, Clinical Research Coordinators |
| End-users in Formulation Development | 70 | Formulation Scientists, Quality Assurance Managers |
The Middle East Sustained Release Excipients Market is valued at approximately USD 1.6 billion, driven by the increasing prevalence of chronic diseases and the demand for controlled drug delivery systems that enhance patient compliance.